Dicerna Pharmaceuticals Announces New Data That Show Dicer-substrate RNA Molecules Produce More Potent, Longer-lasting Gene Silencing Than Shorter siRNA Molecules; Results Published in Journal of Biomolecular Techniques

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, today announced new data published in the current issue of Journal of Biomolecular Techniques (Volume 19, Issue 4), which highlight the significant therapeutic potential of Dicer-substrate 27mers when directly compared with traditional synthetic 21mers.